158 related articles for article (PubMed ID: 37691530)
21. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
[TBL] [Abstract][Full Text] [Related]
22. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK
BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
Miller AE; Olsson TP; Wolinsky JS; Comi G; Kappos L; Hu X; Xu X; Lublin AL; Truffinet P; Chavin J; Delhay JL; Benamor M; Purvis A; Freedman MS;
Mult Scler Relat Disord; 2020 Nov; 46():102438. PubMed ID: 32911306
[TBL] [Abstract][Full Text] [Related]
24. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
Kang C; Blair HA
Drugs; 2022 Jan; 82(1):55-62. PubMed ID: 34897575
[TBL] [Abstract][Full Text] [Related]
25. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
[TBL] [Abstract][Full Text] [Related]
27. Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
Bar-Or A; Montalban X; Hu X; Kropshofer H; Kukkaro P; Coello N; Ludwig I; Willi R; Zalesak M; Ramanathan K; Kieseier BC; Häring DA; Bagger M; Fox E
Neurol Ther; 2023 Feb; 12(1):303-317. PubMed ID: 36534274
[TBL] [Abstract][Full Text] [Related]
28. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Miller AE
Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
[TBL] [Abstract][Full Text] [Related]
30. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
[TBL] [Abstract][Full Text] [Related]
31. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
[TBL] [Abstract][Full Text] [Related]
32. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova EK; Montalban X; Stefoski D; Sprenger T; Robinson RR; Fam S; Smith J; Chalkias S; Giannattasio G; Lima G; Castro-Borrero W
J Neurol; 2020 Oct; 267(10):2851-2864. PubMed ID: 32451615
[TBL] [Abstract][Full Text] [Related]
34. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
[No Abstract] [Full Text] [Related]
35. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
Hemmer B; Wiendl H; Roth K; Wessels H; Höfler J; Hornuss C; Liedert B; Selmaj K
JAMA Neurol; 2023 Mar; 80(3):298-307. PubMed ID: 36689214
[TBL] [Abstract][Full Text] [Related]
36. Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis.
Kramer J; Linker R; Paling D; Czaplinski A; Hoffmann O; Yong VW; Barker N; Ross AP; Lucassen E; Gufran M; Hu X; Zielman R; Seifer G; Vermersch P
Mult Scler J Exp Transl Clin; 2023; 9(4):20552173231203816. PubMed ID: 37829441
[TBL] [Abstract][Full Text] [Related]
37. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K
JAMA Neurol; 2016 Sep; 73(9):1089-98. PubMed ID: 27380540
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS
J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]